Sickle cell disease: Taking a multidisciplinary approach

Journal of the American Academy of Physician Assistants

Volumn 26, Issue 8, 2013, Pages 28-33

  Apanah, Stephanie ^a   Rizzolo, Denise ^b,c  

^a BETH ISRAEL MEDICAL CENTER   (United States)

^b PACE UNIVERSITY   (United States)

^c SETON HALL UNIVERSITY   (United States)

Author keywords

Hemoglobin; Hydroxyurea; Red blood cells; Sickle cell disease; Vaso occlusive crisis

Indexed keywords

ANALGESIC AGENT; ANTISICKLING AGENT; HYDROXYUREA;

ARTICLE; ERYTHROCYTE TRANSFUSION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; PAIN; PATHOPHYSIOLOGY; PNEUMOCOCCAL INFECTION; SICKLE CELL ANEMIA;

ANALGESICS; ANEMIA, SICKLE CELL; ANTISICKLING AGENTS; ERYTHROCYTE TRANSFUSION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; HYDROXYUREA; PAIN; PNEUMOCOCCAL INFECTIONS;

EID: 84881319908     PISSN: 15471896     EISSN: 08937400     Source Type: Journal    
DOI: 10.1097/01.JAA.0000432497.24151.d4     Document Type: Article

References (29)

1. Al-Salem AH. Splenic complications of sickle cell anemia and the role of splenectomy. International Scholarly Research Network Hematology. 2010;2011:1-7
2. A History of Sickle Cell Disease. The Sickle Cell Association of Ontario. http://www.sicklecellontario.org/sickle-cell-101/ a-history-of-sickle-cell- disease
3. Data & Statistics. Centers for Disease Control and Prevention. http://www.cdc.gov/ncbddd/sicklecell/data.html. Accessed October 26, 2012
4. Sharma A, Ford S, Calvert J. Adaptation for life: A review of neonatal physiology. Anesthesia Intens Care Med. 2011;12(3):85-90. http://www.nemsa.net/ neophysiology.pdf
5. Porth CM, Matfi n G. Pathophysiology: Concepts of Altered Health States. 8th edition. Wolters Kluwer Health/Lippincott Williams & Wilkins. 2010
6. Steinberg MH. Sickle cell anemia, the fi rst molecular disease: Overview of molecular etiology, pathophysiology, and therapeutic approaches. Scientifi c World J. 2008;8:1295-1324
7. Fathallah H, Atweh GF. Induction of fetal hemoglobin in the treatment of sickle cell disease. Hematology Am Soc Hematol Educ Program. 2006;58-62
8. Overview of the clinical manifestations of sickle cell disease. UpToDate. Updated August 2012. http://http://www.uptodate. com/contents/overview-of-the- clinical-manifestations-of-sicklecell-disease. Accessed September 19, 2012
9. Harris KM, Haas TS, Eichner ER, Maron BJ. Sickle cell trait associated with sudden death in competitive athletes. 2012. Am J Cardiol. 2012;110(8):1185-1188
10. Facts About Sickle Cell Disease. Centers for Disease Control and Prevention. http://www.cdc.gov/ncbddd/sicklecell/facts.html. Accessed October 26, 2012
11. US Preventive Services Task Force Screening for Sickle Cell Disease in Newborns: Recommendation Statement. Am Fam Physician. 2008;77(9):1300-1302
12. Strouse JJ. Sickle cell disease: Stroke and other complications. Johns Hopkins School of Medicine. Hematology Fellows Conference. July 13, 2012
13. Goldsmith JC, Bonham VL, Joiner CH, et al. Framing the research agenda for sickle cell trait: Building on the current understanding of clinical events and their potential implications. Am J Hematol. 2011;340-346
14. Lanzkron S, Strouse JJ, Wilson R, et al. Systematic review: Hydroxyurea for the treatment of adults with sickle cell disease. Ann Intern Med. 2008;148;939-955
15. Zempsky WT. Evaluation and treatment of sickle cell pain in emergency department: Paths to a better future. Clinical Ped Emerg Med. 2012;11:265-273
16. Ballas SK. Current issues in sickle cell pain and its management. Hematology Am Soc Hematol Educ Prog. 2007:97-105
17. Segal JB, Strouse JJ, Beach MC, et al. Hydroxyurea for the treatment of sickle cell disease. Evidence Report/Technology Assessment. 2008;165:1-298
18. Steinberg MH, McCarthy WF, Castro O, et al. The risks and benefi ts of long-term use of hydroxyurea in sickle cell anemia: A 17.5 year follow-up. Am J Hematol. 2010;403-408
19. Yazdanbakhsh K, Ware RE, Noizat-Pirenne F. Red blood cell alloimmunization in sickle cell disease: Pathophysiology, risk factors, and transfusion management. Blood. 2012;120(3):528-537
20. Defi nition of alloimmunization. eMedicinehealth.com. Accessed November 28, 2012
21. Al-Salem AH. Indications and complications of splenectomy for children with sickle cell disease. J Pediatr Surg. 2006;41(11):1909-1915
22. Whitley-Smith K, Thompson AA. Indications and complications of transfusions in sickle cell disease. Pediatric Blood Cancer. 2012;59:258-364
23. Hsieh MM, Fitzhugh CD, Tisdale JE. Allogeneic hematopoietic stem cell transplantation for sickle cell disease: The time is now. Blood. 2011;118(5):1197-1207
24. Thompson LM, Ceja ME, Yang SP. Stem cell transplantation for treatment of sickle cell disease: Bone marrow versus cord blood transplants. Am J Health-Syst Pharm. 2012;69(15): 1295-1302
25. Cober MP, Phelps SJ. Penicillin prophylaxis in children with sickle cell disease. J Pediatr Pharmacol Ther. 2010;15(3):152-159
26. Nuorti JP, Whitney CG. Prevention of Pneumococcal disease among infants and children-use of 13-valent Pneumococcal conjugate vaccine and 23-valent Pneumococcal polysaccharide vaccine. Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases. December 2010. 59;1-18. http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5911a1. htm
27. McClish DK, Penberthy LT, Bovbjerg VE, et al. Health related quality of life in sickle cell patients: The PiSCES project. Health Quality Life. 2005;3:50
28. Living Well With Sickle Cell Disease Self Care Toolkit. Centers for Disease Control and Prevention. http://www.cdc.gov/ncbddd/ sicklecell/documents/ LivingWell-With-Sickle-Cell%20Disease- Self-CareToolkit.pdf. Accessed October 26, 2012
29. Maakaron JE. Sickle cell anemia workup. http://emedicine. medscape.com/article/205926-workup. Accessed November 14, 2012